Na Li

Na Li, MD, PhD

  • Gastroenterology
  • Hepatology
  • Physician

Clinical Assistant Professor of Internal Medicine

Insurances We Accept


About Me

As a gastroenterologist and hepatologist at The Ohio State University Wexner Medical Center, I see patients in clinic and perform endoscopic procedures. I enjoy working at OSU because it provides comprehensive support for patient care and a robust research environment. This makes it possible for me to provide the most appropriate and individualized care to my patients. In addition, patients also have the opportunity to receive the latest treatments through clinical trials.

My clinical focus is Non-Alcoholic Fatty Liver Disease (NAFLD), which affects about one-quarter of people worldwide. Patients with obesity and type 2 diabetes are at particularly high risk for disease progression (NASH), which often leads to poor health outcomes. Therefore, it is important to raise public awareness of NAFLD and intervene at early stages of the disease. Optimized care for patients with NAFLD requires teamwork among multi-specialty physicians, medical counselors, patients, and their family members. I feel fortunate to be a part of this team and happy to make such a positive impact on my patients’ lives.

When I am not working, I enjoy spending time with family, dancing, and traveling.

Learn more about receiving a tailored approach to treating fatty liver disease at the Ohio State Wexner Medical Center:
  • NAVIGATE study - A seamless, adaptive, phase 2b/3, double-blind, randomized, placebo-controlled, multicenter, international study evaluating the efficacy and safety of belapectin for the prevention of esophageal varices in NASH cirrhosis. Status: Active enrollment.
  • ESSENCE study - The effect of semaglutide in subjects with non-cirrhotic NASH (phase 3). Status: Expected enrollment in September 2021.
  • ENLIVEN study - A randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety and Tolerability of BIO89-100 in subjects with biopsy-confirmed NASH (phase 3). Status: Expected enrollment in October 2021.
  • FASCINATE-2 study - A phase 2b, multi-center, double-blind, randomized, placeobo-controlled study of the safety and efficacy of TVB-2640 in subjects with NASH. Status: Expected enrollment in October 2021
  • REVERSE study - A phase 3, double-blind, randomized, placebo-controlled, multicenter study to evaluate the efficacy and safety of obeticholic acid in subjects with compensated cirrhosis due to non-alcoholic steatohepatitis (NASH). Status: completed enrollment.
  • For more information on these clinical trials, contact Gabrielle Volk (
Additional Languages I Speak
  • Mandarin

Procedures and Conditions I Treat

  • Constipation
  • Hepatitis, Viral, Human
  • Gastrointestinal Hemorrhage
  • Gastroesophageal Reflux
  • Inflammatory Bowel Diseases
  • Irritable Bowel Syndrome
  • Liver Diseases
  • Endoscopy, Gastrointestinal
  • Capsule Endoscopy
  • Digestive System Diseases
  • Fatty Liver
  • Neurosecretory Systems
  • Hepatitis
  • Liver Cirrhosis
  • Colonoscopy
  • Diarrhea
  • Gastroenteritis
  • Peptic Ulcer
  • Celiac Disease
  • Gastroscopy

Locations Where I Practice

Please note: Not all physicians schedule patients at each listed location.

My Videos

Education and Training

Education History

Medical School

Xian Medical University, Xian, Shaanxi 710061,
9/1/1993 - 7/31/1998

Graduate Program

University of Louisville School of Medicine, Louisville, KY
8/20/2001 - 8/5/2005

Post Doctoral Fellow

University of Louisville Hospital, Louisville, KY

9/1/2005 - 6/1/2007


Long Island Jewish Medical Center, New Hyde Park, NY

7/1/2007 - 6/30/2008


Long Island Jewish Medical Center, New Hyde Park, NY

7/1/2008 - 6/30/2010


Long Island Jewish Medical Center, New Hyde Park, NY

7/1/2010 - 6/30/2013

Academic Information

My Department

Internal Medicine

My Division

Gastroenterology, Hepatology and Nutrition

Consulting and Related Relationships

At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the University requires annual disclosures from all faculty members with external interests related to their University responsibilities.

As of 10/25/2021, Dr. Li has reported no relationships with companies or entities.